Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation
Stopped Study discontinued as DSMB determined it was futile. No safety concerns were noted.
Conditions
Interventions
- DRUG: Posoleucel
- DRUG: Placebo
Sponsor
AlloVir